AB-729 (sodium)

AB-729 sodium is a siRNA specifically designed to inhibit viral replication and reduces HBV antigens[1][2]. AB-729 conjugates to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes uptake into hepatocytes via the asialoglycoprotein receptor (ASGR).

[1]Efthymios P Tsounis, et al. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World J Gastroenterol. 2021 Jun 7;27(21):2727-2757.|[2]Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent.